Lung Cancer Staging
Accurate staging of tumors remains the cornerstone of lung cancer management and prognostication. The tumor, node, metastasis (TNM) system (TNM system) currently in use for the classification of non-small cell lung cancer (NSCLC) was first proposed more than 50 years ago by Denoix and was later adapted by the American Joint Committee for Cancer Staging in 1974. Subsequently, this staging system was revised in 1986, 1997, and more recently in 2009 resulting in the 7th edition of the TNM classification for lung cancer staging.
The TNM system considers the anatomical spread of cancer by factors of tumor size and invasion, extent of lymphatic spread, and presence of metastatic disease, thereby dictating current strategies for clinical and surgical staging investigations. Emphasis is on the detection of cytological and histological spread by means of noninvasive staging, such as imaging, or invasive staging, such as endoscopic or surgical biopsy. New on the horizon include...
KeywordsPositron Emission Tomography Standard Uptake Value NSCLC Patient Mediastinal Lymph Node Sentinel Node Mapping
- Liptay MJ, D’amico TA, Nwogu C, Demmy TL, Wang XF, Gu L, Litle VR, Swanson SJ, Kohman LJ (2009) Thoracic surgery subcommittee of the cancer and leukemia group B. Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. J Thorac Oncol 4:198–202CrossRefPubMedGoogle Scholar
- Meyers BF, Haddad F, Siegel BA, Zoole JB, Battafarano RJ, Veeramachaneni N, Cooper JD, Patterson GA (2006) Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg 131(4):822–829CrossRefPubMedGoogle Scholar
- van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA, van Velthoven PC, Comans EF, Diepenhorst FW, Verboom P, van Mourik JC, Postmus PE, Boers M, Teule GJ (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359:1388–1393CrossRefPubMedGoogle Scholar